Jueves 23/04/2020 ventas de casas nuevas

[admin]

https://lta.reuters.com/articulo/apple- ... AKCN22527Y

[admin]

https://lta.reuters.com/articulo/mercad ... AKCN2252BZ

[admin]

LAST CHG %CHG
Crude Oil Futures 16.99 3.21 23.29
Brent Crude Futures 21.98 1.61 7.90
Gold Futures 1754.20 15.90 0.91
Silver Futures 15.570 0.235 1.53
DJIA Futures 23512 156 0.67
S&P 500 Futures 2812.75 24

[admin]

LAST CHG %CHG
DJIA 23851.01 375.19 1.60
S&P 500 2818.83 19.52 0.70
Nasdaq Composite 8631.89 136.51 1.61
Japan: Nikkei 225 19429.44 291.49 1.52
UK: FTSE 100 5817.95 47.32 0.82
Crude Oil Futures 17.60 3.82 27.72
Gold Futures 1758.60 20.30 1.17
Yen 107.84 0.09 0.09
Euro 1.0792

[admin]

AAPL comprara $100 billones de sus propias acciones.

[admin]

+335.23

[admin]

https://www.bvl.com.pe/

[admin]

https://money.cnn.com/data/dow30/

[admin]

New York antibody study estimates 13.9% of residents have had the coronavirus, Gov. Cuomo says
PUBLISHED THU, APR 23 202011:53 AM EDTUPDATED MOMENTS AGO
Noah Higgins-Dunn
@HIGGINSDUNN
GP: Coronavirus Governor Andrew Cuomo Press Conference in Albany, US - 106498924
New York Governor Andrew Cuomo (D) speaks during a press Conference at the State Capitol.
Michael Brochstein | Barcroft Media | Getty Images
An estimated 13.9% of the New Yorkers have likely had Covid-19, according to preliminary results of coronavirus antibody testing released by Gov. Andrew Cuomo on Thursday.

The state randomly tested 3,000 people at grocery stores and shopping locations across 19 counties in 40 localities, Cuomo said.


“What we found so far is that the state-wide number is 13.9% tested positive for having the antibodies. What does that mean? It means these were people who were infected and who developed the antibodies to fight the infection,” he said. “They were infected three weeks ago, four weeks ago, five weeks ago, six weeks ago, but they had the virus, they developed the antibodies and they are now recovered.’”

[admin]

GILD su medicina remdesivir no mejoró a los pacientes en su primera fase.
GILD a la baja.

+227.46

[admin]

Stocks quickly cut gains after report says potential Gilead virus treatment flops in trial
PUBLISHED WED, APR 22 20206:06 PM EDTUPDATED MOMENTS AGO
Fred Imbert
@FOIMBERT
Thomas Franck
@TOMWFRANCK
Stocks slashed earlier gains on Thursday after a report said Gilead Sciences’ remdesivir flopped in a Chinese trial aimed at treating coronavirus patients.

The Dow Jones Industrial Average was up 116 points, or 0.5%, after jumping more than 400 points earlier in the day. The S&P 500 was up just 0.4% along with the Nasdaq Composite. Both indexes were up more than 1% earlier in the session.


The Financial Times said — citing documents accidentally published by the World Organization — that remdesivir did not improve patients’ condition or reduce the coronavirus pathogen in their bloodstream. Gilead Sciences shares were down more than 3% after a brief volatility halt.

Gildead said that the WHO document had “inappropriate characterisations of the study,” according to the FT. “As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease,” the company told the paper.

Stocks surged Friday after STAT News reported that Chicago patients taking remdesivir to treat coronavirus were recovering rapidly from severe virus symptoms.

Equities had initially rallied as crude prices continued their rebound from historic lows.

West Texas Intermediate futures for June delivery jumped 30% to $18 per barrel as traders increased bets on U.S. production cuts. WTI also rallied on Wednesday.

Earlier in the week, concerns over a lack of energy demand sent WTI’s May contract — which expired Tuesday — into a negative price. Crude prices are also down sharply year to date even after their strong gains over the past two days.

“The resulting price action is highly damaging for many oil producers, and certainly implies a sharp fallback in US shale fracking, contributing to much weaker US exports and capex later this year,” wrote Charles Dumas, chief economist at TS Lombard.

Oil’s rebound helped equities claw back some of their steep losses from earlier in the week. Between Monday and Tuesday, the S&P 500 and Dow dropped more than 4% before rallying around 2% on Wednesday.

CH 20200326 Stock market wild swings 10am.png
“Large single day advances can’t alone solve the market’s woes. But they can be part of the solution,” said Frank Cappelleri, executive director at Instinet, regarding Wednesday’s gains.

He noted the average gain for the S&P 500 since the March bottom has been much larger than its average decline. “This kind [of] scenario is what helps bullish patterns succeed and bearish patterns fade away… which is what we’ve seen happen over the last month of trading.”

The major averages have staged a massive rebound since hitting a coronavirus-crisis low on March 23. In that time, the Dow, S&P 500 and Nasdaq are all up over 20%. Still, the major averages remain well below the record highs set in February.

CH 20200422 SP500 looking for a bottom
U.S. traders on Thursday also pored through the Labor Department’s latest report on jobless claims.

Another 4.4 million workers filed for unemployment benefits last week, according to data from the Labor Department. That brought the five-week jobless claims total to more than 26 million, erasing all the job gains since the Great Recession. However, Thursday’s print represented a decline from the jobless claims number reported in the previous week.

“The decline in initial jobless claims … is encouraging, but the damage has already been done,” said Paul Ashworth, chief U.S. economist at TS Lombard. He added, however, that the “easing of lockdowns may have pulled some people currently on temporary layoff back into paid employment. If so, then April’s unemployment rate could prove to be the pandemic peak.”

On the earnings front, CSX shares gained more than 3% after the railroad company posted quarterly profits that beat expectations. Union Pacific also got a boost from stronger-than-forecast earnings.

Click here for the latest news on the coronavirus.

Subscribe to CNBC PRO for exclusive insights and analysis, and live business day programming from around the world.

[admin]

LAST CHG %CHG
DJIA 23586.92 111.10 0.47
S&P 500 2806.72 7.41 0.26
Nasdaq Composite 8525.20 29.82 0.35
Japan: Nikkei 225 19429.44 291.49 1.52
UK: FTSE 100 5826.61 55.98 0.97
Crude Oil Futures 16.51 2.73 19.81
Gold Futures 1747.60 9.30 0.54
Yen 107.49 -0.25 -0.23
Euro 1.0782

[admin]

https://money.cnn.com/data/dow30/

[admin]

Copper April 23,13:38
Bid/Ask 2.3073 - 2.3085
Change +0.0115 +0.50%
Low/High 2.2803 - 2.3279
Charts

Nickel April 23,13:34
Bid/Ask 5.4650 - 5.4718
Change +0.0915 +1.70%
Low/High 5.3463 - 5.5119
Charts

Aluminum April 23,13:39
Bid/Ask 0.6632 - 0.6634
Change -0.0024 -0.36%
Low/High 0.6591 - 0.6698
Charts

Zinc April 23,13:37
Bid/Ask 0.8403 - 0.8407
Change -0.0152 -1.78%
Low/High 0.8334 - 0.8607
Charts

Lead April 23,13:38
Bid/Ask 0.7360 - 0.7364
Change -0.0064 -0.86%
Low/High 0.7345 - 0.7497
Charts

Uranium Apr 20, 2020
Ux U308 price: 32.00
Change from

[admin]

Stocks close flat after wild session as investors assess Gilead coronavirus treatment
PUBLISHED WED, APR 22 20206:06 PM EDTUPDATED MOMENTS AGO
Fred Imbert
@FOIMBERT
Thomas Franck
@TOMWFRANCK
WATCH NOW
VIDEO00:01
There are bargains to be had in this market: Stock picker
Stocks were taken for a wild ride on Thursday that showed just how important finding a treatment for the coronavirus is for Wall Street.

The Dow Jones Industrial Average slashed a 400-point gain and nearly went negative after The Financial Times said — citing documents accidentally published by the World Health Organization — that Gilead Sciences’ drug remdesivir did not improve patients’ condition or reduce the coronavirus pathogen in their bloodstream. Those findings, according to the report, came from a clinical trial in China.


The S&P 500 and Nasdaq Composite cut their gains on the report, while Gilead was briefly halted for volatility.

But the major averages rebounded after Gilead took issue with the report, saying: “Because this study was terminated early due to low enrollment, it was underpowered to enable statistically meaningful conclusions. As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease.”

Around 3 p.m., the Dow was up 228 points, or nearly 1%. The S&P 500 and Nasdaq climbed 0.7% and 0.8%, respectively. Gilead shares were still down more than 3% even after taking exception with the report.

The report and Gilead’s subsequent statement came a week after STAT News reported that Chicago patients taking remdesivir to treat coronavirus were recovering rapidly from severe virus symptoms. That report lifted market sentiment, sending stock sharply higher.

“Any sort of treatment is key for people to getting people back out into the world,” said Kim Forrest, founder of Bokeh Capital, on CNBC’s “The Exchange.” “When the results were announced of the trial last week, you could see the market react and it was a sigh of relief that, if I get this, I may not die.”

CH 20200326 Stock market wild swings 10am.png
Oil rebound continues

West Texas Intermediate futures for June delivery jumped 19.7% to settle at $16.50 per barrel as traders increased bets on U.S. production cuts. WTI also rallied on Wednesday.

Earlier in the week, concerns over a lack of energy demand sent WTI’s May contract — which expired Tuesday — into a negative price. Crude prices are also down sharply year to date even after their strong gains over the past two days.

“The resulting price action is highly damaging for many oil producers, and certainly implies a sharp fallback in US shale fracking, contributing to much weaker US exports and capex later this year,” wrote Charles Dumas, chief economist at TS Lombard.

Oil’s rebound helped equities claw back some of their steep losses from earlier in the week. Between Monday and Tuesday, the S&P 500 and Dow dropped more than 4% before rallying around 2% on Wednesday.

“Large single day advances can’t alone solve the market’s woes. But they can be part of the solution,” said Frank Cappelleri, executive director at Instinet, regarding Wednesday’s gains.

He noted the average gain for the S&P 500 since the March bottom has been much larger than its average decline. “This kind [of] scenario is what helps bullish patterns succeed and bearish patterns fade away… which is what we’ve seen happen over the last month of trading.”

The major averages have staged a massive rebound since hitting a coronavirus-crisis low on March 23. In that time, the Dow, S&P 500 and Nasdaq are all up over 20%. Still, the major averages remain well below the record highs set in February.

CH 20200422 SP500 looking for a bottom
U.S. traders on Thursday also pored through the Labor Department’s latest report on jobless claims.

Another 4.4 million workers filed for unemployment benefits last week, according to data from the Labor Department. That brought the five-week jobless claims total to more than 26 million, erasing all the job gains since the Great Recession. However, Thursday’s print represented a decline from the jobless claims number reported in the previous week.

“The decline in initial jobless claims … is encouraging, but the damage has already been done,” said Paul Ashworth, chief U.S. economist at TS Lombard. He added, however, that the “easing of lockdowns may have pulled some people currently on temporary layoff back into paid employment. If so, then April’s unemployment rate could prove to be the pandemic peak.”

On the earnings front, CSX shares gained more than 1% after the railroad company posted quarterly profits that beat expectations. Union Pacific also got a boost from stronger-than-forecast earnings.

Click here for the latest news on the coronavirus.

Subscribe to CNBC PRO for exclusive insights and analysis, and live business day programming from around the wor